|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis - Peroxisome Proliferator-Activated Receptor (PPAR) Agonists
La Merie Publishing, Aug 2010, Pages: 45
The present Competitive Intelligence Report about PPAR Agonists provides a competitor evaluation in the field of peroxisome proliferator-activated receptor targeting small molecule agonists for treatment of type 2 diabetes and/or dyslipidemia as of August 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Despite the tremendous attrition rate of PPAR agonist R&D over the last 20 years, the ones in the market are commercially quite successful and spur development of improved successors. The current reassessment of benefit/risk ratio of the classical PPAR gamma agonist rosiglitazone by the FDA and the EMA highlights the need for safer PPAR agonists. One promising approach to achieve effective, but still well tolerated PPAR gamma agonists are selective PPAR gamma modulating agents. Other approaches try to combine PPAR alpha, gamma and delta agonism in one molecule and to find the right balance.
The report includes a compilation of marketed products and current active projects in research and development of PPAR Agonists in type 2 diabetes and/or dyslipidemia. In addition, the report lists company-specific R&D pipelines of PPAR agonists. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Competitor Analysis: Targeted Therapy of Diabetes
Competitor Analysis: Obesity & Diabetes
Competitor Analysis: Diabetes Drug Pipeline
Competitor Analysis: Obesity
Competitor Analysis: Cholesterol Management
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
Competitor Analysis - Targeted Therapy of Obesity
Competitor Analysis - Toll-Like Receptor (TLR) Agonists and Antagonists 2010
Competitor Analysis: Adenosine Receptor Agonists & Antagonists
Non-Insulin Diabetes. Management Products, Players, Markets, and Forecasts
|
|
|
|
